Information Provided By:
Fly News Breaks for December 5, 2019
DMTK
Dec 5, 2019 | 08:51 EDT
Lake Street analyst Thomas Flaten initiated coverage of DermTech with a Buy rating and $15 price target. The company is on the verge of offering dermatologists a highly accurate melanoma diagnostic at lower cost and with better outcomes than standard of care, Flaten tells investors in a research note. With the upcoming full commercial launch of its gene expression- based, adhesive patch biopsy product, the Pigmented Lesion Assay, and a "broad" pipeline of opportunities, DermTech is "poised to deliver robust long-term growth," contends the analyst.
News For DMTK From the Last 2 Days
There are no results for your query DMTK